Central and Peripheral Glutamatergic Biomarkers Delineate Three Distinct Phenotypes in Olanzapine-Treated Schizophrenia
Key Insights
A cross-sectional study of 51 adults with schizophrenia (search) on chronic olanzapine treatment identified three phenotypic subgroups using central and peripheral glutamatergic biomarkers.
Higher serum serotonin correlated with more severe negative symptoms (ρ=0.32, p=0.029), while elevated cingulate Glx ratios were linked to greater depressive burden (ρ=0.31, p=0.031).
Hierarchical clustering revealed a low-symptom dose-efficient group, a high-symptom dose-resistant group with cingulate hypoglutamatergia, and a younger hyperglutamatergic neurodevelopmental-profile group.
A new cross-sectional observational study has identified three distinct clinical phenotypes among olanzapine-treated patients with schizophrenia (search) by integrating central and peripheral glutamatergic biomarkers, offering a potential framework for biomarker-guided personalized therapy in a condition marked by highly heterogeneous treatment responses.
Investigators enrolled 51 adults with schizophrenia (search) receiving chronic olanzapine treatment (mean duration of 5.6 years) and combined clinical assessments with peripheral neurochemical profiling and magnetic resonance spectroscopy (MRS) of the anterior and posterior cingulate cortices. The study, published in Nature, represents the first effort to integrate central and peripheral glutamatergic biomarkers with multivariate phenotyping in a naturalistic olanzapine-treated cohort.
Key Neurochemical Associations
Partial correlations controlling for age, sex, and treatment duration revealed several significant associations. Higher serum serotonin levels correlated with more severe negative symptoms (ρ = 0.32, p = 0.029), while increased cingulate Glx ratios were linked to greater depressive burden (ρ = 0.31, p = 0.031). Elevated serum glutamic acid was associated with overall psychopathology, whereas lower serum and cingulate glutamine levels were related to more severe symptoms and higher olanzapine exposure.
Three Phenotypic Subgroups Emerge
Using hierarchical clustering on principal components (HCPC), the researchers identified three distinct subgroups. The first comprised low-symptom, dose-efficient responders who achieved symptom control with relatively low olanzapine exposure. The second group consisted of high-symptom, dose-resistant patients characterized by cingulate hypoglutamatergia—reduced Glx levels in the cingulate cortex. The third subgroup included younger individuals with elevated Glx ratios and moderate olanzapine exposure, a profile the authors describe as suggestive of a hyperglutamatergic, neurodevelopmental trajectory.
The authors emphasize that these findings are exploratory in nature. "These findings are exploratory and warrant prospective validation to determine their potential utility for biomarker-guided treatment stratification in schizophrenia (search)," they note.
Implications for Precision Psychiatry
The study demonstrates that central and peripheral glutamatergic markers can delineate distinct clinical phenotypes of olanzapine response in schizophrenia (search), shaped by both neurochemical and demographic factors. Stratification based on glutamatergic profiles and symptom patterns may contribute to the development of precision psychiatry approaches, potentially helping clinicians identify which patients are most likely to benefit from olanzapine and which may require alternative therapeutic strategies.
The research was conducted under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, and the authors call for prospective studies to confirm whether these biomarker-defined subgroups can prospectively predict treatment outcomes and guide clinical decision-making.